About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

T-cell Lymphoma >  ASCO 2012 - T-cell Lymphoma

Last update: 06/01/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

Comments or Questions?

 

Alternating non-cross-resistant multi-agent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
 
Multicenter, phase II study of Bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial. | 2012 ASCO Annual Meeting Abstracts
 
Central nervous system involvement in T-cell lymphomas: A single center experience. | 2012 ASCO Annual Meeting Abstracts
 
Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. | 2012 ASCO Annual Meeting Abstracts
 
Positron emission tomography scan (PET) in human T-cell lymphotropic virus-1 (HTLV) associated adult T-cell leukemia lymphoma (ATLL): Single center experience. | 2012 ASCO Annual Meeting Abstracts
MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study. | 2012 ASCO Annual Meeting Abstracts
 
Phase III study of investigational MLN8237 (alisertib) versus investigator's choice in patients (pts) with relapsed/refractory (rel/ref) peripheral T-cell lymphoma (PTCL). | 2012 ASCO Annual Meeting Abstracts
 
Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL). | 2012 ASCO Annual Meeting Abstracts
 
Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. | 2012 ASCO Annual Meeting Abstracts
 
Progression-free survival for subsequent relapses in patients with peripheral T-cell lymphoma (PTCL). | 2012 ASCO Annual Meeting Abstracts
 
Long-term follow-up results of a phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma (NKTCL): JCOG0211. | 2012 ASCO Annual Meeting Abstracts
 
Gastrointestinal tract NK/t cell lymphoma: Clinical features, management, and prognosis of 47 patients. | 2012 ASCO Annual Meeting Abstracts
 
Effect of sunlight exposure on survival in patients with lymphoma: Results from the prospective Singapore Lymphoma Study. | 2012 ASCO Annual Meeting Abstracts
 
Effect of a combination of epigenetic agents on the malignant phenotype in models of T-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
 
Long-term follow-up and secondary malignancy in mycosis fungoides patients treated by electron beam irradiation. | 2012 ASCO Annual Meeting Abstracts
 
Anti-CD3 immunotoxin to induce remissions in cutaneous T-cell lymphoma patients. | 2012 ASCO Annual Meeting Abstracts
 
Epidemiologic, clinical, and pathologic features of lymphomas at the Peruvian hospital: Hospital Nacional Cayetano Heredia. | 2012 ASCO Annual Meeting Abstracts
 
Phase Ib study of plitidepsin (APL) with gemcitabine (GEM) in refractory solid tumors and lymphoma patients. | 2012 ASCO Annual Meeting Abstracts
 
First-in-human phase I trial of NHS-IL12 in advanced solid tumors. | 2012 ASCO Annual Meeting Abstracts
 
 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.